Catalyst Wire Dossier Catalyst Wire Dossier

Galegenimab

FHTR2163 · Genentech, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Galegenimab, covering 2023-10-16 to 2024-03-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) [Phase 2]

See pricing